...
首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >the role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives
【24h】

the role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives

机译:放射疗法在1999年有限期霍奇金病中的作用:局限性和前景

获取原文
获取原文并翻译 | 示例
           

摘要

The role of radiotherapy in limited stage Hodgkin's disease (HD) has been gradually changing in the past few decades, resulting in the almost complete disappearance of exclusive irradiation treatment. In reality, exclusive radiotherapy yielded satisfactory results in terms of long-term survival, but in 1999 it was becoming impossible not to take into account the late mortality rates observed in all large cohorts of HD patients. This increased mortality rate has been shown to be related to 1) cardiac toxicity of irradiation, and 2) secondary radiation-induced solid tumors. Thus, the search for efficient but less toxic new strategies can no longer be avoided. For clinically staged, limited HD, precisely defined according to specific prognostic factors, the association of chemotherapy and radiotherapy appears more and more as a standard, and with this therapeutic burden comes parallel efforts for its alleviation. The Previous Radiotherapy experience has shown that, after a chemotherapy-induced complete remission, irradiation of only the initially involved areas was enough. Ongoing trials are now exploring the possibility of a dose de-escalation, from the conventional 36 Gy to 20 Gy (as for children HD), and to maybe 0 Gy (no radiotherapy at all). In parallel, deescalation in the number of chemotherapy cycles is also being investigated. For unfavorable cases, the problem is slightly different, as a higher percentage of cases still appears to be refractory to treatment in this subgroup. Thus, while chemo-radiotherapy has clearly became the standard strategy, efforts are essentially being devoted to identify new--and hopefully more efficient--chemotherapy schemes. In Europe, most of these pending questions will be addressed in the recently initiated trials of the EORTC/GELA and of the GHSG (German Hodgkin Study Group), with the aim of offering to patients treatment which could be at least as efficient as the present schedules, and less toxic in the long term.
机译:在过去的几十年中,放射治疗在有限期霍奇金病(HD)中的作用已逐渐发生变化,导致独家放射治疗几乎完全消失。实际上,独家放疗在长期生存方面取得了令人满意的结果,但是在1999年,不考虑所有大型HD患者的晚期死亡率成为不可能。已经显示出这种增加的死亡率与1)辐射的心脏毒性和2)继发性辐射诱发的实体瘤有关。因此,不再能够避免寻求有效但毒性较小的新策略。对于根据特定的预后因素精确定义的临床阶段性局限性HD,越来越多地将化学疗法和放疗疗法的关联作为标准,并伴随着这种治疗负担来减轻其负担。先前的放射疗法经验表明,在化学疗法诱导的完全缓解后,仅照射最初涉及的区域就足够了。现在正在进行的试验正在探索剂量降低的可能性,从传统的36 Gy降低到20 Gy(对于儿童HD),甚至可能是0 Gy(完全没有放疗)。同时,也正在研究化疗周期数的下降。对于不利的病例,问题略有不同,因为该亚组中仍有较高比例的病例对治疗难以治愈。因此,尽管化学放射疗法已明显成为标准策略,但实际上仍在努力寻找新的化学疗法,并希望能更有效地进行化学疗法。在欧洲,大多数这些悬而未决的问题将在EORTC / GELA和GHSG(德国霍奇金研究小组)最近启动的试验中解决,目的是为患者提供至少与目前一样有效的治疗时间表,从长远来看毒性较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号